Abstract: Background: Tacrolimus, for its activity on modulation of collagen production and fibroblast activity, may have a role in the prevention of hypertrophic scars. oBjectives: Evaluate macroscopic, microscopic, metabolic, laboratory effects and side effects of the use of topical tacrolimus ointment, in different concentrations, in the prevention of hypertrophic scars. Methods: Twenty-two rabbits were submitted to the excision of 2 fragments of 1 cm of each ear, 4 cm apart, down to cartilage. The left ear of the animals was standardized as control and Vaseline applied twice a day. The right ear received tacrolimus ointment, at concentrations of 0.1% on the upper wound and 0.03% on the lower wound, also applied twice a day. Macroscopic, microscopic, laboratory criteria and the animals' weight were evaluated after 30 days of the experiment. results: Wounds treated with tacrolimus, at concentrations of 0.1% and 0.03%, when compared to control, showed a lower average degree of thickening (p = 0.048 and p <0.001, respectively). The average of scar thickness and lymphocyte, neutrophil and eosinophil concentrations are lower in the treated wounds compared to the control (p <0.001, p=0.022, p=0.007, p=0.044, respectively). The mean concentration of lymphocytes is lower in wounds treated with a higher concentration of the drug (p=0.01). study liMitations: experiment lasted only 30 days. conclusions: Tacrolimus at the 2 concentrations evaluated reduced the severity of inflammatory changes and positively altered the macroscopic aspect of the scar in the short term. Its use was shown to be safe, with no evidence of systemic or local adverse effects.
sian adults in the second and third decades of life, with no gender predilection, coming from tropical areas. The Afro-American population has a 10% incidence of keloids. [3] [4] Keloid pathogenesis is not yet fully understood, but it is known that there is an increased deposition of extracellular matrix, which can extend from the dermis to the subcutis. Besides, there is an inflammatory reaction and dermal fibroblasts with increased activity and fibrin hyperproliferation, reduction or absence of elastic fibers can be seen. It usually occurs due to the loss of the balance between collagen production and degradation. Tacrolimus is a macrolide immunomodulator produced in the Tsukuba region in Japan, originated from Streptomyces tsukubaensis, discovered in 1984. 6 It inhibits the phosphorylation of transcription factors, a process mediated by calcineurin, resulting in the inhibition of the synthesis of inflammatory cytokines that would be produced by T lymphocytes (IL-2, IL-3, IL4, IL-5, TNF-α and granulocyte stimulating factors). 7 In this way, it inhibits the activation of mast cells and neutrophils and affects the function of basophils, eosinophils and Langerhans cells. 8 The medication is used to prevent keloid due to its action in the activity of fibroblasts and modulation of the collagen produc-
tion. An experimental study in rabbits using tacrolimus intradermally showed satisfactory results for the prevention of hypertrophic scarring. 9 However, there are no studies in the literature using the medication topically, in ointment, with the same goal. The number of studies using tacrolimus for the prevention of unsightly scarring is still very little, making its use for this purpose still restricted.
The objective of this study was to evaluate the macroscopic, microscopic, metabolic, laboratory effects and possible side effects of the use of different concentrations of tacrolimus ointment for the prevention of hypertrophic scarring, using the model of rabbits' ears. Twenty-two male, white, New Zealand rabbits (Oryctolagus cuniculus), aged around two months were used. The initial weight of the animals was 2.16 kg. The animals were identified by numbers and placed into individual cages, in an appropriate place, with controlled ventilation and lighting. They were fed with a particular commercial food and had ad libitum water throughout the period of the experiment. Their excrements were removed daily and discarded in specific containers.
METHODS
All animals went through a period of approximately 48
hours of adaptation and observation of the state of health, with assessment of vital signs and clinical examination before the first surgical procedure.
On the day of the first surgical procedure, blood samples were collected through venipuncture of the auricular vein and after the death of the animals on the 30 th day of the experiment, new samples were collected through intra-cardiac puncture. The samples were processed and urea (UR), creatinine (CR), alanine transaminase (ALT), albumin (ALB) and gamma-glutamyl transferase (GGT)
were dosed.
The rabbits were anesthetized in the left gluteal region with an intramuscular injection of ketamine 45mg/kg associated to xylazine 7 mg/kg. Throughout the anesthetic induction and during the surgical procedure the vital signs were checked and voluntary movements were evaluated. Two animals died during anesthetic induction.
The ventral skin of the rabbits' ears was marked with a gauge with two 1 cm diameter circles 4 cm apart in a straight line in order to avoid interaction between the wounds. Circular fragments were excised from the marking down to cartilage, including perichondrium ( Figure 1 ).
The animals' wounds were distributed into two main groups by a draw after the surgical procedure. The surgeon did not know to which group each wound belonged whilst performing the procedure.
The left ear was standardized as control and was treated with Vaseline twice a day. The right ear of the animals was treated with tacrolimus ointment 0.1% on the upper wound and ointment 0.03% on the lower wound, also applied twice a day.
Macroscopic criteria: degree of scar thickening and local erythema.
Microscopic criteria: thickness of the normal dermis, scar length, scar thickness, and concentration of capillaries, lymphocytes, neutrophils, eosinophils, granulomas, and macrophages were evaluated on day 30 of the experiment.
Macroscopic criteria were assessed in in vivo animals by two observers, in order to reduce single observer bias. A scale to determine the degree of erythema was adopted: 0 corresponds to no erythema; 1 to subtle erythema located in some areas of the scar; Throughout the statistical analysis, continuous data were tested for normality with the Kolmogorov-Smirnov test, that indicated normality present in variables and therefore, the class of parametric tests was used.
To compare the means of independent groups, Student's t-test and for paired groups, the paired t-test were used.
In all tests, the significance level of 5% was used, therefore differences are significant considering p<= 0.05.
RESULTS
The mean weight of the animals was higher after 30 days of the experiment when compared to the mean before surgery ( Figure 2 ). Inclusion cysts in three wounds, micro-abscesses in two wounds, crust formation in three wounds and dermal hemorrhage in one wound were the microscopic changes described in the left ear,
i.e., the control ear that was only treated with the vehicle (Figure 6 ).
The mean creatinine and alanine transaminase levels was higher after 30 days of the experiment when compared to before the surgery (p<0.001). The mean levels of gamma-glutamyl transferase and albumin were lower after the intervention when compared to before the procedure (p<0.001) ( Table 1 ).
The mean scar thickness and concentration of lymphocytes, neutrophils and eosinophils was lower in the wounds treated with the medication when compared to control (p<0.001, p=0.022, p=0.007, p=0.044, respectively) ( Table 2) .
When comparing the upper wounds, between tacrolimus 0.1% and control, significant differences were observed in the following: concentration of lymphocytes, neutrophils, granulomas, and macrophages, with lower mean concentrations in the wounds treated than in controls (p=0.013; 0.024; 0.023; 0.027) and scar thickness, also with a lower mean in the treated group (p=0.012). Still comparing the upper wounds, for thickness of the normal dermis and concentration of capillaries, the mean values were higher for treated wounds (p=0.012 and p<0.001, respectively) ( Table 3 ). 
DISCUSSION
Superficial wounds, i.e., excoriations that only affect the epidermis, rarely progress to a keloid or hypertrophic scar. Unsightly scars usually become visible macroscopically around one to three months after the triggering trauma. When these data are added, the most obvious histological changes in the reticular dermis, such as newly formed vessels, increased concentration of fibroblasts and collagen deposition point to the fact that unsightly scars, keloids and hypertrophic scars arise from a chronic inflammatory process in the reticular dermis that begins at the time of the injury and continues for months. 13 The choice of the follow-up period of 30 days for the wounds after the initial injury was established based in reference studies and the availability of the researchers, but a study with a 90 days follow-up period could offer complementary results.
Tacrolimus is still not found in the standardized medication list for the topical treatment of unsightly scars, because there are few studies regarding this use of the medication. including studies using tacrolimus, 9 but none of them used tacrolimus ointment.
The choice of the concentrations used, the administration route and tacrolimus vehicle, 0.1% and 0.03% topical ointment, was based on the availability and ease of access in the market and previous studies with other administration routes and concentrations and positive results, 9 and on reports of improvement of scars in patients using the medication in the concentration and route tested for the treatment of atopic dermatitis. 16, 17 Another reason to use the medication as an ointment was the existence of a previous study that tested it as the single intradermal injection and raised the question whether the medication would be effective as a cream or an ointment, since it would take longer to achieve therapeutic concentrations in the dermis, where the healing process takes place. 9 In the literature, the association of tacrolimus to progressive nephropathy when present systemically is well-documented. 18 Serum creatinine only would not be the best indicator of renal func-
tion. An association of this marker to creatinine clearance would be a more accurate indicator. 19, 20 Studies in mice demonstrate that animals with chronic kidney disease are affected with more adverse events from tacrolimus related to nephrotoxicity. These mice had higher levels of serum creatinine, lower levels of creatinine clearance and more weight-loss. 21 The normal levels of serum creatinine in rabbits range between 0.51 to 1.53 mg/dL and such levels can vary according to the seasons, according to Spinelli MO et al. 22, 23 Despite the differences in the level of serum creatinine before and after the experiment, the mean of the values is below the higher reference limit, indicating lack of significant impairment in the rabbits' renal function, what can be corroborated by the weight gain seen throughout the experiment, ruling out systemic adverse events from tacrolimus.
Biochemical tests to evaluate liver function can be divided into indicative of hepatocellular injury, which are the ones that evaluate aminotransferases, and indicative of cholestasis, based in alkaline phosphatase and gamma-glutamyl transferase levels. 24 The mean serum alanine transaminase in animals after the intervention was higher than before the intervention, with a twofold increase of the initial level, suggesting that this variation might not be due to pathological causes, but to environmental causes. According to Abfadel et al, 25 increases between 15 and 100 times of the liver aminotransferases could be observed in the acute phase of hepatitis; whereas in hepatic steatosis the serum levels tend to be mildly elevated.
Alanine transaminase is also found in muscle and heart cells and is not as specific for liver disease as aspartate transaminase. Gamma-glutamyl transferase is present in the cells of the bile ducts, heart, pancreas and can be increased by drugs such as corticosteroids and anticonvulsants. 26, 24 The reduction in the mean serum levels of gamma-glutamyl transferase during the experiment is in accordance with the suggestion of possible environmental causes for the increase in alanine transaminase. Inverse changes of such liver markers would not be justified if there was any pathological involvement of the animals' liver. For rabbits, gamma-glutamyl transferase reference levels are between 2IU and 15IU. 22 At the end of the experiment, the animals showed GGT levels within the normal range. Unfortunately, some samples were hemolyzed and a N of less than 20 was adopted to evaluate GGT. Currently, tacrolimus has been used to prevent re-stenosis in patients submitted to placement of stents, what was treated for many years in the past with brachytherapy, a procedure also used to treat keloid scars. 29, 30 By analogy, we can infer that if brachytherapy was beneficial for the treatment of hypertrophic scars, tacrolimus might also be. Gisquet et al. 9 demonstrated the beneficial effect of tacrolimus when used intradermally in a single dose for the prevention of hypertrophic scarring in their study and showed that such effect was dose-dependent. They used three concentrations of the medication: the lower concentration had poorer results while the higher concentration proved to be the most effective.
When applied topically, the following are considered adverse events of tacrolimus: atrophy, depigmentation, telangiectasias, infection and necrosis, besides weight loss. 9 None of these events were seen in any of the wounds analyzed. The fact that less erythema was seen in wounds exposed to the higher concentration Macrophages are attracted to the scar during the inflammation phase by the activity of TGF-β. With TGF-β being inhibited by the activity of the medication in healing, it is expected that the mean concentration of macrophages in these treated wounds be lower. 36 Granulomas can occur as a response to a foreign body or to external microorganisms. The fact that there was less formation of granulomas in the wounds treated with tacrolimus confirms the statement that there was no secondary infection present in the treated wounds, this being one of the adverse events of the drug reported in the literature. 
